These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 26108239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H, Austrian Breast and Colorectal Cancer Study Group.
    J Natl Cancer Inst; 2007 Dec 19; 99(24):1845-53. PubMed ID: 18073378
    [Abstract] [Full Text] [Related]

  • 3. [Aromatase inhibitors and arthralgia].
    Nagykálnai T, Landherr L, Mészáros E.
    Magy Onkol; 2011 Mar 19; 55(1):32-9. PubMed ID: 21617789
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
    Sendur MA, Aksoy S, Zengin N, Altundag K.
    J BUON; 2013 Mar 19; 18(4):838-44. PubMed ID: 24344006
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P, Frassoldati A.
    Breast J; 2007 Mar 19; 13(1):28-35. PubMed ID: 17214790
    [Abstract] [Full Text] [Related]

  • 9. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
    Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE.
    J Clin Oncol; 2015 Jan 20; 33(3):265-71. PubMed ID: 25512454
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.
    Am J Manag Care; 2006 Jul 20; 12(7):374-86. PubMed ID: 16834524
    [Abstract] [Full Text] [Related]

  • 12. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
    Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL.
    Breast Cancer Res Treat; 2017 Jul 20; 164(2):411-419. PubMed ID: 28451964
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group.
    Lancet; 2017 Jul 20; 365(9453):60-2. PubMed ID: 15639680
    [Abstract] [Full Text] [Related]

  • 15. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC.
    Oncology; 2005 Jul 20; 69(6):471-7. PubMed ID: 16410685
    [Abstract] [Full Text] [Related]

  • 16. Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
    Thomas R, Williams M, Marshall C, Walker L.
    Br J Cancer; 2008 May 06; 98(9):1494-9. PubMed ID: 18392053
    [Abstract] [Full Text] [Related]

  • 17. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug 06; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 18. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 06; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
    Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group.
    Lancet Oncol; 2008 Sep 01; 9(9):866-72. PubMed ID: 18703382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.